<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01241305</url>
  </required_header>
  <id_info>
    <org_study_id>VCRC5510</org_study_id>
    <secondary_id>U54AR057319-06</secondary_id>
    <nct_id>NCT01241305</nct_id>
  </id_info>
  <brief_title>One-Time DNA Study for Vasculitis</brief_title>
  <official_title>VCRC Genetic Repository One-Time DNA Protocol</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Office of Rare Diseases (ORD)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Rare Diseases Clinical Research Network</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Pennsylvania</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to identify genes that increase the risk of developing
      vasculitis, a group of severe diseases that feature inflammation of blood vessels. Results of
      these studies will provide vasculitis researchers with insight into the causes of these
      diseases and generate new ideas for diagnostic tests and therapies, and will be of great
      interest to the larger communities of researchers investigating vasculitis and other
      autoimmune, inflammatory, and vascular diseases.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The systemic vasculitides comprise several inflammatory diseases of blood vessels, usually
      arteries, which may cause systemic, multi-organ disease that can result in substantial
      morbidity and increased mortality. Each type of vasculitis is a rare (&quot;orphan&quot;) disease.
      However, taken together, vasculitis affects tens of thousands of Americans and is responsible
      for substantial morbidity and mortality and almost one billion dollars per year in hospital
      care alone. While the vasculitides share the trait of vascular inflammation, the unique
      disease phenotypes, clinical courses, differences in prognoses, and responses to therapy
      suggest that important differences exist in pathogenesis. The Vasculitis Clinical Research
      Consortium (VCRC) currently focuses on 6 specific types of vasculitis that were selected to
      represent a balance between unmet medical and scientific needs, prevalence in North America,
      feasibility of study, and an interest in studying a spectrum of small, medium, and large
      vessel vasculitides.

      The great majority of published studies on the genetics of vasculitis have used modest-sized
      cohorts that are only suitable for investigation of a few candidate genes at a time, or to
      detect large effect sizes, so that replicated findings are highly skewed to the HLA region.
      Larger and more ambitious genetic studies in vasculitis are expected to generate numerous
      hypotheses for translational research in gene expression, biochemistry, and molecular
      pathology.

      A one-time collection of clinical data and DNA would substantially increase the sample sizes
      for genetic association studies in all six vasculitides studied in the VCRC. Many patients
      are seen at participating VCRC centers but do not enroll in the Longitudinal Studies. These
      patients often are interested in participating in research studies but cannot return
      frequently for visits, usually due to distance from the VCRC centers. This approach would be
      particularly useful for the rarer forms of vasculitis under study (Takayasu's Arteritis
      (TAK), Polyarteritis Nodosa (PAN), eosinophilic granulomatosis with polyangiitis
      (Churg-Strauss) (EGPA) and also for Giant Cell Arteritis (GCA), since elderly patients have
      been particularly likely to decline participation in the Longitudinal Studies due to travel
      constraints.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2010</start_date>
  <completion_date type="Anticipated">August 2018</completion_date>
  <primary_completion_date type="Anticipated">August 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation of clinical data and linked DNA specimens.</measure>
    <time_frame>1 year.</time_frame>
  </primary_outcome>
  <enrollment type="Anticipated">1300</enrollment>
  <condition>Eosinophilic Granulomatosis With Polyangiitis (Churg-Strauss)</condition>
  <condition>Giant Cell Arteritis</condition>
  <condition>Granulomatosis With Polyangiitis (Wegener's)</condition>
  <condition>Microscopic Polyangiitis</condition>
  <condition>Polyarteritis Nodosa</condition>
  <condition>Takayasu's Arteritis</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Two 10 ml tubes of blood will be collected for DNA extraction.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Individuals with giant cell arteritis, Takayasu's arteritis, polyarteritis nodosa,
        granulomatosis with polyangiitis (Wegener's), microscopic polyangiitis, and eosinophilic
        granulomatosis with polyangiitis (Churg-Strauss). Enrollment will be sequential and
        patients will have disease in various stages and of different duration.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        1. Diagnostic criteria for Giant Cell Arteritis Age at disease onset &gt;50 years (required)

          1. New onset or new type of localized pain in the head

          2. Temporal artery abnormality (i.e. temporal artery tenderness to palpation or decreased
             pulsation, unrelated to arteriosclerosis of cervical arteries)

          3. ESR of &gt;40mm in the first hour by the Westergren method

          4. Abnormal artery biopsy (i.e. temporal artery biopsy showing vasculitis characterized
             by a predominance of mononuclear cell infiltration or granulomatous inflammation,
             usually with multinucleated giant cells)

          5. Large Vessel Vasculitis (LVV) by angiogram or biopsy not explained by something else

        Inclusion Criteria:

        2. Diagnostic criteria for Takayasu's Arteritis

          1. Age at disease onset &lt;50 years

          2. Claudication of extremities

          3. Decreased brachial artery pulse (one or both arteries)

          4. Blood pressure difference of &gt;10mm Hg between the arms

          5. Bruit over subclavian arteries or aorta

          6. Arteriogram abnormalities compatible with TAK (includes conventional dye angiography
             or MR angiography or CT angiography)

        Inclusion Criteria:

        3. Diagnostic criteria for Polyarteritis Nodosa Major criteria (not explained by other
        causes) felt by investigator to be due to vasculitis

          1. Arteriographic abnormality

          2. Presence of granulocyte or mixed leukocyte infiltrate in an arterial wall on biopsy

          3. Mononeuropathy or polyneuropathy

        Minor criteria (not explained by other causes) felt by investigator to be due to vasculitis

          1. Weight loss &gt; 4 kg

          2. Livedo reticularis, cutaneous ulcerations, or skin nodules

          3. Testicular pain or tenderness

          4. Myalgias

          5. Diastolic blood pressure &gt; 90 mm Hg

          6. Elevated BUN or serum creatinine levels

          7. Ischemic abdominal pain

        Isolated cutaneous Polyarteritis Nodosa 1. Biopsy-proven cutaneous PAN

        Inclusion Criteria:

        4. Diagnostic criteria for Granulomatosis with Polyangiitis (Wegener's) (GPA) and
        Microscopic Polyangitis (MPA)

          -  Diagnosis of GPA or MPA. Widely accepted diagnostic criteria, as opposed to
             classification criteria or definitions, have not been developed for GPA &amp; MPA.

          -  For diagnosis of GPA meets at least 2 of the following 5 modified ACR criteria:

               1. Nasal or oral inflammation with oral ulcers or nasal discharge with pus or blood

               2. Abnormal chest radiograph with nodules, fixed infiltrates, or cavities

               3. Urinary sediment with microhematuria or red cell casts

               4. Granulomatous inflammation within the wall of an artery or in the perivascular
                  area on biopsy

               5. Antineutrophil cytoplasmic antibody (ANCA) positive by enzyme immunoassay for
                  either PR3- or MPO-ANCA

          -  For diagnosis of MPA, meets the Chapel Hill Consensus Conference Definition for MPA:

               1. Necrotizing vasculitis, with few or no immune deposits, that affects small
                  vessels (i.e., capillaries, venules, arterioles)

               2. Necrotizing arteritis involving small- and medium-sized arteries may be present

               3. Necrotizing glomerulonephritis is very common

               4. Pulmonary capillaritis often occurs

                  Inclusion Criteria:

                  5. Diagnostic criteria for Eosinophilic Granulomatosis with Polyangiitis
                  (Churg-Strauss)

                    1. Asthma

                    2. Peak peripheral blood eosinophilia of &gt;10% of total WBC

                    3. Peripheral neuropathy attributable to vasculitis

                    4. Transient pulmonary infiltrates on chest imaging studies

                    5. Paranasal sinus abnormalities or nasal polyposis

                    6. Eosinophilic inflammation on tissue biopsy

                  If patients have 4 of the above 6 criteria but lack clearcut documentation of
                  small vessel vasculitis, they are also eligible for enrollment.

                  General Exclusion Criteria:

          -  Inability to give informed consent and to sign the consent form

          -  Enrolled in VCRC protocols 5502, 5503, 5504, 5505, 5506, 5522, or 5523

          -  Unwilling to provide blood for DNA collection
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>7 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter Merkel, MD, MPH</last_name>
    <role>Study Director</role>
    <affiliation>University of Pennsylvania</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Carol McAlear, MA</last_name>
    <email>cmcalear@upenn.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cedars-Sinai Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julie Thai</last_name>
      <email>julie.thai@cshs.org</email>
    </contact>
    <investigator>
      <last_name>Lindsy Forbess, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California, San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sharon Chung, MD</last_name>
      <email>Sharon.Chung@ucsf.edu</email>
    </contact>
    <investigator>
      <last_name>Sharon Chung, MD, MAS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60208</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mary Carns</last_name>
      <email>m-carns@northwestern.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Kansas Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Caitlin McMillian</last_name>
      <email>cmcmillian@kumc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Boston University School of Medicine</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02118</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Naomi Amudala, NP</last_name>
      <phone>617-414-2512</phone>
      <email>namudala@bu.edu</email>
    </contact>
    <investigator>
      <last_name>Paul Monach, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109-5422</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emily Lewis</last_name>
      <email>eelewis@med.umich.edu</email>
    </contact>
    <investigator>
      <last_name>Ora Singer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>am Hughes</last_name>
      <email>Hughes.Samantha@mayo.edu</email>
    </contact>
    <contact_backup>
      <last_name>Jane Jaquith</last_name>
      <phone>507-284-4502</phone>
      <email>jaquith.jane@mayo.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Ulrich Specks, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Steven Ytterberg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital for Special Surgery</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Annel Fernandez</last_name>
      <email>fernandeza@HSS.EDU</email>
    </contact>
    <investigator>
      <last_name>Robert Spiera, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elizabeth Kisela</last_name>
      <email>kiselae@ccf.org</email>
    </contact>
    <investigator>
      <last_name>Carol Langford, MD, MHS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>B.Minal Hatwar</last_name>
      <email>Bhagyavati.Hatwar@uphs.upenn.edu</email>
    </contact>
    <investigator>
      <last_name>Peter Merkel, MD, MPH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15261</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laurie Hope</last_name>
      <email>hopelk@upmc.edu</email>
    </contact>
    <investigator>
      <last_name>Larry Moreland, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jessica Gonzalez</last_name>
      <email>jessica.gonzalez@hsc.utah.edu</email>
    </contact>
    <investigator>
      <last_name>Curry Koening, MD, MS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Joseph's Healthcare</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sandra Messier</last_name>
      <phone>905-522-1155</phone>
      <phone_ext>35873</phone_ext>
      <email>smessier@stjoes.ca</email>
    </contact>
    <investigator>
      <last_name>Nader Khalidi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5T 3L9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Judy Vendramini</last_name>
      <email>judy.vendramini@sinaihealthsystem.ca</email>
    </contact>
    <investigator>
      <last_name>Simon Carette, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Istanbul University</name>
      <address>
        <city>Istanbul</city>
        <state>Fatih</state>
        <zip>34452</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Turkey</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://rarediseasesnetwork.org/vcrc/</url>
    <description>Vasculitis Clinical Research Consortium</description>
  </link>
  <link>
    <url>http://rarediseasesnetwork.epi.usf.edu/</url>
    <description>Rare Diseases Clinical Research Network</description>
  </link>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 22, 2010</study_first_submitted>
  <study_first_submitted_qc>November 15, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 16, 2010</study_first_posted>
  <last_update_submitted>April 23, 2018</last_update_submitted>
  <last_update_submitted_qc>April 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 25, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Pennsylvania</investigator_affiliation>
    <investigator_full_name>Peter Merkel</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Vasculitis</keyword>
  <keyword>CSS</keyword>
  <keyword>EGPA</keyword>
  <keyword>GCA</keyword>
  <keyword>GPA</keyword>
  <keyword>WG</keyword>
  <keyword>MPA</keyword>
  <keyword>PAN</keyword>
  <keyword>TAK</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vasculitis</mesh_term>
    <mesh_term>Arteritis</mesh_term>
    <mesh_term>Systemic Vasculitis</mesh_term>
    <mesh_term>Giant Cell Arteritis</mesh_term>
    <mesh_term>Polymyalgia Rheumatica</mesh_term>
    <mesh_term>Granulomatosis with Polyangiitis</mesh_term>
    <mesh_term>Microscopic Polyangiitis</mesh_term>
    <mesh_term>Takayasu Arteritis</mesh_term>
    <mesh_term>Aortic Arch Syndromes</mesh_term>
    <mesh_term>Churg-Strauss Syndrome</mesh_term>
    <mesh_term>Polyarteritis Nodosa</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

